|Awarded On||August 20, 2014|
|Title||Next Generation Sequencing-Based Approaches for the Development of Epigenetic Biomarkers for Predicting Therapeutic Outcome in Patients With Colorectal Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Ajay Goel|
Colorectal cancer (CRC) is one of the most common cancers worldwide; and is the second-leading cause of cancer-related deaths in the United States, with an estimated 50,000 deaths annually. For patients with more advanced disease, chemotherapeutic treatments are unavoidable. In spite of the advances we have made in the recent years, we have not been very successful in developing chemotherapeutic drugs that are predictively safe, effective and non-toxic. At the moment we have few individualized treatment options for CRC patients, and most patients end up receiving similar treatments, which may provide benefit, or perhaps harm. Over the years we have learned that individual CRCs are quite diff...